EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Potent EGFR Inhibitors for Del19 and L858R / T790M Mutants Through Structure‐Based Virtual Screening and Biological Evaluation

Ting Xu, Yuchen Zhao, Mengfei Chen, Lijuan Zuo, Hanshuang Cai, Yuguo Liu, Chuanfeng Liu iD, Jing Shi

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Ting Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and In…. Hauptthemen laut MEDLINE: ErbB Receptors, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Province Traditional Chinese Medicine Science and Technology Project, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) mutation‐mediated drug resistance represents a major clinical challenge in the treatment of non‐small cell lung cancer (NSCLC). In this study, the lead compound XJ2‐2 was identified through structure‐based virtual screening. It exhibited potent anti‐proliferative activity against both EGFR Del19 mutant PC‐9 cells and EGFR L858R/T790M mutant H1975 cells, with IC 50 values of 0.88 ± 0.12 μM and 0.77 ± 0.09 μM, respectively. Mechanistic studies have demonstrated that XJ2‐2 directly targets and binds to the EGFR, thereby effectively inhibiting EGFR phosphorylation and its downstream signaling pathways in both in vitro and in vivo models. In tumor‐bearing mouse models, XJ2‐2 significantly reduced tumor burden. Preclinical safety evaluation indicated that no treatment‐related toxicity was observed for XJ2‐2 at all tested doses. With its novel molecular scaffold and mutant‐selective inhibitory profile, XJ2‐2 represents a promising lead compound for overcoming NSCLC drug resistance and advancing the development of next‐generation EGFR inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimalsCell Line, TumorLung NeoplasmsMutationMiceCarcinoma, Non-Small-Cell LungMolecular Docking SimulationCell ProliferationDrug Resistance, NeoplasmStructure-Activity Relationship

Stichwörter der Autor:innen

EGFR inhibitorEGFRDel19EGFRL858R/T790Mdrug resistancestructure‐based virtual screening

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy (Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Med…
  • Taian Central Hospital General ICU Zone 2, Taian, China.

ORCID-Profile: Chuanfeng Liu

Förderung

  • Shandong Province Traditional Chinese Medicine Science and Technology Project
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Xu, T., Zhao, Y., Chen, M., Zuo, L., Cai, H., Liu, Y., Liu, C., & Shi, J. (2026). Discovery of Potent EGFR Inhibitors for Del19 and L858R / T790M Mutants Through Structure‐Based Virtual Screening and Biological Evaluation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70391

Vancouver

Xu T, Zhao Y, Chen M, Zuo L, Cai H, Liu Y, et al. Discovery of Potent EGFR Inhibitors for Del19 and L858R / T790M Mutants Through Structure‐Based Virtual Screening and Biological Evaluation. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70391

BibTeX
@article{Xu2026,
  author = {Xu, Ting and Zhao, Yuchen and Chen, Mengfei and Zuo, Lijuan and Cai, Hanshuang and Liu, Yuguo and Liu, Chuanfeng and Shi, Jing},
  title = {Discovery of Potent EGFR Inhibitors for Del19 and L858R / T790M Mutants Through Structure‐Based Virtual Screening and Biological Evaluation},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70391}
}
Kostenlos starten →